News

ODU breaks ground on $184M biosciences building

Old Dominion University on Monday broke ground on the biggest capital project in the 95-year-old university’s history — a new biological sciences building.

The planned five-story, 162,586 square-foot building will be located on ‘s campus in , near the university’s Oceanography and Mills Godwin Life Sciences buildings.

ODU spokesperson Jonah Ross Grinkewitz said the $184 million project is funded by a state bond issue and will house classrooms, teaching laboratories, a 120-seat lecture hall and other student support spaces. State and campus leaders, and community members gathered Monday to commemorate the .

“Today would not be possible without significant support from the Commonwealth of Virginia,” said President Brian O. Hemphill in a Monday statement. “With the leadership and action of Gov. Youngkin and the General Assembly, a $184 million investment has been made in Old Dominion University, specifically our students, representing the largest in the history of our institution in terms of both scope and size.”

The building is meant to support faculty and student research in biomedical and ecological areas. As part of the project, the Arthur and Phyllis Kaplan Orchid Conservatory will be relocated within the biological sciences building with an added water feature and a two-story tropical display house. The exterior design incorporates an existing pond and features a terraced seating area.

A team that includes VMDO Architects, Ballinger and O’Shea Wilson Site Works designed the building. Newport News-based will serve as the project’s general contractor.

The building is expected to be ready for use in spring 2028.

Virginia Secretary of Education Aimee Guidera said the building embodies the ODU’s mission of being a “forward-focused, innovative and entrepreneurial research university.

“The pioneering biological research conducted at this state-of-the-art research and development hub will prepare students to succeed in their lives and careers beyond graduation,” Guidera added in a statement.

Read more here.

 

Recent News

10/17/2025

BRAINBox Solutions Announces Publication in JAMA Network OPEN of Major Analysis of Initial HeadSmart II Trial Concussion Patients

BRAINBox Solutions today announced the publication in JAMA Network OPEN of a major analysis of the first 1,000 patients with suspected concussion (mild traumatic brain injury or mTBI) in its pivotal, HeadSMART II study of its initial test, BRAINBox TBI, for concussion diagnosis and prognosis. The analysis, the largest of its kind, identified patient characteristics

10/16/2025

Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food and Drug Administration (FDA) Commissioner’s National Priority Voucher (CNPV) Pilot Program. This designation recognizes Phlow’s leadership in advancing domestic manufacturing of essential and life-changing medicines

10/16/2025

Civica To Launch Long-Acting Insulin Glargine in the US in January 2026

Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price in the current long-acting insulin market. Civica insulin glargine will be available in the United States beginning January 1, 2026. In California, the product will carry the “CalRx” brand. “Civica will provide insulin